Atherectomy Devices

Atherectomy Devices

Global Atherectomy Devices Market to Reach US$1.9 Billion by 2030

The global market for Atherectomy Devices estimated at US$983.0 Million in the year 2023, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 9.6% over the analysis period 2023-2030. Support Devices, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$142.9 Million by the end of the analysis period. Growth in the Rotational Atherectomy Devices segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$265.5 Million While China is Forecast to Grow at 13.6% CAGR

The Atherectomy Devices market in the U.S. is estimated at US$265.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$417.4 Million by the year 2030 trailing a CAGR of 13.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.8% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Global Atherectomy Devices Market - Key Trends and Drivers Summarized

Why Are Atherectomy Devices Crucial in Cardiovascular Interventions?

Atherectomy devices have become essential tools in the management of peripheral and coronary artery disease, conditions characterized by the accumulation of atherosclerotic plaque within the arteries. These devices are used to remove or debulk plaque from arterial walls, thereby restoring blood flow and reducing the risk of serious complications such as heart attacks, strokes, and limb amputations. Unlike traditional angioplasty, which primarily compresses plaque against the artery walls, atherectomy physically removes the plaque, offering a more definitive solution in certain cases. The importance of atherectomy devices is underscored by their use in treating complex lesions that are difficult to manage with standard angioplasty and stenting techniques. As cardiovascular disease continues to be a leading cause of morbidity and mortality worldwide, the role of atherectomy devices in enhancing patient outcomes and expanding treatment options remains critical.

How Are Technological Advancements Improving the Efficacy of Atherectomy Devices?

Technological advancements have significantly improved the efficacy and safety of atherectomy devices, driving innovation in the field of interventional cardiology. Modern atherectomy devices are designed to be more precise, minimizing the risk of damage to the arterial walls while effectively removing calcified and fibrotic plaque. The development of directional atherectomy, which allows for targeted plaque removal, has enabled physicians to treat more complex and calcified lesions with greater accuracy. Additionally, advancements in rotational and orbital atherectomy devices have enhanced their ability to navigate tortuous vessels and treat lesions that were previously considered inoperable. These devices now often come equipped with imaging capabilities, such as intravascular ultrasound (IVUS) or optical coherence tomography (OCT), which provide real-time visualization of the artery during the procedure. This integration of imaging technology allows for more informed decision-making and precise plaque removal, reducing the likelihood of complications and improving long-term outcomes for patients.

What Market Trends Are Influencing the Adoption of Atherectomy Devices?

Several market trends are influencing the adoption of atherectomy devices, reflecting the broader shifts in cardiovascular care and treatment strategies. The increasing prevalence of peripheral artery disease (PAD) and coronary artery disease (CAD), driven by factors such as aging populations, rising obesity rates, and the global increase in diabetes, is leading to greater demand for advanced interventional tools like atherectomy devices. Additionally, there is a growing trend towards minimally invasive procedures, as both patients and healthcare providers seek to reduce recovery times, hospital stays, and overall healthcare costs. Atherectomy devices, with their ability to effectively treat complex lesions through a minimally invasive approach, align well with this trend. The expanding body of clinical evidence supporting the efficacy of atherectomy in improving long-term patient outcomes is also driving adoption. Furthermore, the development of next-generation devices that offer enhanced safety profiles and the ability to treat a wider range of lesion types is expanding the indications for atherectomy and making it a more attractive option in cardiovascular interventions.

What Factors Are Driving the Growth of the Atherectomy Devices Market?

The growth in the atherectomy devices market is driven by several factors that are reshaping the landscape of cardiovascular care. A primary driver is the increasing incidence of cardiovascular diseases, particularly peripheral artery disease (PAD) and coronary artery disease (CAD), which are major contributors to morbidity and mortality globally. Technological advancements in device design and imaging integration are also propelling market growth by improving the safety and efficacy of atherectomy procedures. The trend towards minimally invasive surgical techniques is further boosting demand, as atherectomy offers an effective option for patients with complex or heavily calcified lesions that are not well-suited to traditional angioplasty or stenting. Additionally, the expansion of healthcare infrastructure in emerging markets, coupled with increasing awareness of advanced interventional cardiology techniques, is contributing to the growth of the atherectomy devices market. As these factors continue to evolve, the market for atherectomy devices is expected to experience sustained growth, driven by innovation, expanding indications, and the increasing global burden of cardiovascular diseases.

Select Competitors (Total 16 Featured) -

• Abbott Laboratories
• Avinger, Inc.
• B. Braun Melsungen AG
• Biomerics, LLC
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• C.R Bard, Inc.
• Cardinal Health, Inc.
• Koninklijke Philips NV
• Medtronic PLC
• Minnetronix, Inc.
• Ra Medical Systems, Inc.
• Straub Medical AG
• Terumo Corporation

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.